08:59 AM EST, 02/06/2025 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) on Thursday said it is advancing its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed with Pharma Inventor, will be synthesized and delivered for further evaluation, it added.

According to a statement, these new compounds are targeting "unmet needs" in oncology, including central nervous system malignancies.

Separately, the statement noted, the company expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR (Ataxia Telangiectasia and Rad3-related protein). The company announced last month that it had achieved a shortlist of AI-generated molecules targeting the condition.

"The addition of these AI-designed compounds significantly broadens our pipeline potential and will accelerate progress toward delivering life-changing treatments," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics ( RKVTF ). "By rapidly scaling our efforts, we are addressing the growing demand for innovative cancer therapies with unprecedented precision and speed."

RKV saw its shares drop $0.025 or 11.6% on Wednesday, but remains at the high end of its 52 week trading range.